Mahmoud Mosli
Overview
Explore the profile of Mahmoud Mosli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
564
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aljohani H, Anbarserry D, Mosli M, Ujaimi A, Bakhshwin D, Elango R, et al.
Biomedicines
. 2025 Feb;
13(2).
PMID: 40002872
: Vedolizumab (VDZ) is the new monoclonal drug targeting α4β7 integrin for patients with moderate/severe IBD. Between 30 and 45% of patients fail to respond to VDZ after 14-16 weeks...
2.
AlMuhaidib S, Bzeizi K, AlAmeel T, Mosli M, Khoja B, Barakeh D, et al.
Saudi J Gastroenterol
. 2024 Dec;
PMID: 39660608
Background: The prevalence of inflammatory bowel disease (IBD) continues to increase worldwide, including in the Arab world. This study investigates IBD research output in Arab countries from 2009 to 2023,...
3.
Ngoma A, Mutombo P, Mosli M, Omokoko M, Nollet K, Ohto H
Vox Sang
. 2024 Dec;
PMID: 39657987
Background And Objectives: Restless legs syndrome (RLS), with adverse health outcomes, has been linked to blood donation, but evidence published thus far has not been rigorously analysed. This systematic review...
4.
Alsahafi M, Salah F, Mimish H, Hejazi M, Alkhiari R, Alkhowaiter S, et al.
Saudi J Gastroenterol
. 2024 Aug;
30(6):376-380.
PMID: 39157889
Background: Erosive esophagitis (EE) is frequently present in patients with gastroesophageal reflux disease (GERD), some of which may not have GERD symptoms. The prevalence of EE in the Saudi population...
5.
Alharbi O, Farsakh N, Al-Awadhi S, Al-Taweel T, Mikhail I, Batwa F, et al.
Gastro Hep Adv
. 2024 Aug;
3(2):190-200.
PMID: 39129949
Background And Aims: Treatments for ulcerative colitis (UC) differ in safety, efficacy, and route of administration; patient preferences for treatment attributes should be considered in treatment decisions. No study to...
6.
Alghamdi M, Alyousfi D, Mukhtar M, Mosli M
Saudi J Gastroenterol
. 2024 Jun;
30(6):346-352.
PMID: 38847060
Background: The medical treatment of ulcerative colitis (UC) includes the use of biological agents such as vedolizumab, a gut-selective alpha4beta7 (ɑ4β7) antagonist. The mechanism of action of vedolizumab involves interfering...
7.
AlDhneem H, AlMutairdi A, Attamimi M, Mosli M, AlAmeel T, Al-Bawardy B
Saudi J Gastroenterol
. 2024 Jun;
30(4):260-265.
PMID: 38841910
Background: Recent advancement and complexity in the management of inflammatory bowel disease (IBD) has made it challenging for gastroenterology (GI) fellows to obtain competency and confidence in managing the complex...
8.
Alghamdi W, Mosli M, Alqahtani S
Ther Adv Endocrinol Metab
. 2024 Apr;
15:20420188241242937.
PMID: 38628492
Metabolic dysfunction-associated fatty liver disease (MAFLD), formerly known as nonalcoholic fatty liver disease, is becoming a significant contributor to chronic liver disease globally, surpassing other etiologies, such as viral hepatitis....
9.
Mosli M
Inflamm Intest Dis
. 2024 Apr;
9(1):71-84.
PMID: 38586860
Introduction: Multiple therapies are currently available for inflammatory bowel disease (IBD); it is therefore crucial to understand patterns of drug change. This study aimed to examine the patterns of biological...
10.
Alsahafi M, Mosli M, Alkhowaiter S, Donnellan F
Value Health Reg Issues
. 2023 Nov;
39:1-5.
PMID: 37967489
Objectives: The optimal strategy of Helicobacter pylori eradication in patients with duodenal ulcer is unclear. In this study, we aimed to compare the utility and the ulcer recurrence rate using...